Skip to main content
. 2018 Feb 27;16:44. doi: 10.1186/s12967-018-1414-x

Table 1.

Participants’ characteristics by illness groups

Characteristicsa All
(n = 639)
CFS-X
(n = 77, 12%)
CFS
(n = 64, 10%)
ISF
(n = 302, 47%)
NF
(n = 196, 31%)
p-value
Age, mean (SEM) 48.07 (0.38) 49.99 (1.11) 47.75 (1.21) 48.06 (0.58) 47.44 (0.68) 0.2725
BMI, mean (SEM) 28.13 (0.21) 28.29 (0.56) 28.86 (0.68) 28.82 (0.32) 26.77 (0.36) 0.0003
WHR (SEM) 0.85 (0.00) 0.85 (0.01) 0.85 (0.01) 0.86 (0.004) 0.83 (0.01) 0.0025
Sex 0.0009
 Female 477 (74.64%) 64 (83.12%) 58 (90.63%) 222 (73.51%) 133 (67.87%)
Race 0.0127
 White 488 (76.37%) 60 (77.92%) 51 (79.69%) 219 (72.51%) 158 (80.61%)
 Black 139 (21.75%) 13 (16.88%) 10 (15.63%) 79 (26.16%) 37 (18.88%)
 Other 12 (1.87%) 4 (5.19%) 3 (4.69%) 4 (1.32%) 1 (0.51%)
Residential area 0.1621
 Urban 216 (33.80%) 26 (33.77%) 22 (34.38%) 109 (36.09%) 59 (30.10%)
 Metro 106 (16.58%) 7 (9.09%) 7 (10.94%) 49 (16.23%) 43 (21.94%)
 Rural 317 (49.61%) 44 (57.14%) 35 (54.69%) 144 (47.68%) 94 (47.96%)
Education < 0.0001
 Less than High School 34 (5.33%) 13 (16.88%) 2 (3.13%) 14 (4.65%) 5 (2.56%)
 ≥ HS ≤ 2 year College 349 (54.78%) 51 (66.23%) 40 (62.50%) 177 (58.80%) 81 (41.54%)
 4-year College 110 (17.27%) 5 (6.49%) 7 (10.94%) 47 (15.61%) 51 (26.15%)
 Graduate 144 (22.60%) 8 (10.39%) 15 (23.44%) 63 (20.93%) 58 (29.74%)
Income < 0.0001
 ≤ $20,000 78 (12.74%) 22 (31.88%) 9 (14.75%) 41 (14.04%) 6 (3.16%)
 $20,001–$40,000 102 (16.67%) 9 (13.04%) 12 (19.67%) 59 (20.21%) 22 (11.58%)
 ≥ $40,001 432 (70.59%) 38 (55.07%) 40 (65.57%) 192 (65.75%) 162 (85.26%)
Illness duration in year, mean (SEM)b 10.99 (0.95) 9.83 (1.10) 12.40 (1.61) Not applicable Not applicable 0.1796
Post-exertional malaise
 Yes 191 (29.89%) 65 (84.42%) 52 (81.25%) 70 (23.18%) 4 (2.04%) < 0.0001

aValues for age, BMI, WHR and illness duration are mean (SEM). Values for all other characteristics are number of participants with percentages in parenthesis

bNumber of subjects with information on illness duration were 86, 47 and 39 corresponding to columns All, CFS-X and CFS